Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
April 18, 2023
Assignee:
Endeavor Biomedicines, Inc.
Inventors:
Miguel de los Rios, John Hood, Anita Difrancesco